Aarti Pharmalabs Limited - Asset Resilience Ratio
Aarti Pharmalabs Limited (AARTIPHARM) has an Asset Resilience Ratio of 1.69% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AARTIPHARM current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Aarti Pharmalabs Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see AARTIPHARM total asset value.
Liquid Assets Composition Over Time
This chart breaks down Aarti Pharmalabs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Aarti Pharmalabs Limited carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs491.23 Million | 1.69% |
| Total Liquid Assets | Rs491.23 Million | 1.69% |
Asset Resilience Insights
- Limited Liquidity: Aarti Pharmalabs Limited maintains only 1.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Aarti Pharmalabs Limited Industry Peers by Asset Resilience Ratio
Compare Aarti Pharmalabs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.35% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Annual Asset Resilience Ratio for Aarti Pharmalabs Limited (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Aarti Pharmalabs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.69% | Rs491.23 Million ≈ $5.31 Million |
Rs29.06 Billion ≈ $314.32 Million |
-1.04pp |
| 2024-03-31 | 2.73% | Rs703.98 Million ≈ $7.61 Million |
Rs25.82 Billion ≈ $279.24 Million |
+0.45pp |
| 2023-03-31 | 2.27% | Rs509.90 Million ≈ $5.51 Million |
Rs22.44 Billion ≈ $242.68 Million |
-- |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more